Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Mineralys Therapeutics (Nasdaq: MLYS) reported that on August 10, 2026, a majority of its independent directors granted inducement equity awards to newly appointed Chief Medical Officer Dr. Terry Ferguson under the 2025 Employment Inducement Incentive Award Plan.

The grant includes a stock option for 135,000 shares of common stock and a restricted stock unit (RSU) award for 102,400 shares. The option vests over four years, with 25% vesting on the first anniversary of the vesting commencement date, August 10, 2026, and the remainder vesting in equal monthly installments over the following three years, subject to continued service. The RSUs vest in four equal annual installments over four years starting August 10, 2026, also subject to continued service. According to Mineralys, these awards were granted as an inducement material to Dr. Ferguson’s employment, in line with Nasdaq Listing Rule 5635(c)(4).

Argus Aug 14 session 1 alert

-1.63% close to close 3.5x rel. volume Open Argus

Details

News Market Reaction – MLYS

$2.31B Market Cap

On Aug 14, the first trading day after this news, MLYS closed 1.63% below the previous close. Relative volume reached 3.5x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 14 session.

Market Context

The prior inducement-award report, news_id 1087304, was followed by a -0.96% 24-hour move. The curre...

Analysis

The prior inducement-award report, news_id 1087304, was followed by a -0.96% 24-hour move. The current announcement adds a CMO grant, while net selling remains a relevant context factor to monitor.

Key Figures

Option award: 135,000 shares RSU award: 102,400 shares Option vesting period: 4 years +3 more

Option award

135,000 shares

Inducement stock option award granted August 10, 2026

RSU award

102,400 shares

Inducement restricted stock unit award granted August 10, 2026

Option vesting period

4 years

Subject to continued service

Initial option vesting

25%

Vests on the first anniversary of August 10, 2026

Monthly option vesting

1/48th

Vests following each one-month period thereafter

RSU vesting installments

4 equal installments

Over the first four anniversaries of August 10, 2026

Historical Context

5 past events · Latest: Aug 11

5 events

1. Aug 11

   2Q26 earnings report

   24h Move

   -1.0%

   Quarterly loss widened while the company advanced lorundrostat toward potential commercialization.

2. Aug 04

   Earnings date announcement

   24h Move

   +2.8%

   The company scheduled second-quarter results and an investor conference call.

3. Jul 27

   Inducement awards

   24h Move

   -1.0%

   New employees received stock options and restricted stock unit awards.

4. Jun 08

   Healthcare conference

   24h Move

   +7.5%

   Management participated in the Goldman Sachs Global Healthcare Conference.

5. Jun 08

   Clinical data presentation

   24h Move

   -5.0%

   The company announced a late-breaking lorundrostat biomarker data presentation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock unit, Nasdaq Listing Rule 5635(c)(4), employment inducement incentive award plan

3 terms

restricted stock unit financial

"an inducement restricted stock unit award covering 102,400 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

employment inducement incentive award plan financial

"under Mineralys’ 2025 Employment Inducement Incentive Award Plan"

An employment inducement incentive award plan is a program that gives new hires upfront or time‑based rewards—often company stock, options or cash—designed to persuade talent to join and stay. Think of it as a signing bonus that vests over time to align the new employee’s interests with the company’s future performance. Investors care because these awards create ongoing costs and can dilute existing ownership, while shaping management incentives and retention.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on August 10, 2026, a majority of the independent directors of Mineralys’ Board of Directors granted an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares of Mineralys common stock to Dr. Terry Ferguson, Mineralys’ newly appointed Chief Medical Officer.

The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option award will vest over a four-year period, with 25% of the total shares underlying the option vesting on the first anniversary of the award’s vesting commencement date, August 10, 2026, and 1/48th of the total shares underlying the option vesting following each one-month period thereafter, subject to continued service. The restricted stock unit award will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the award’s vesting commencement date, August 10, 2026, subject to continued service. The awards were granted as an inducement material to Dr. Ferguson entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Contact:

Investor Relations

investorrelations@mineralystx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity awards did Mineralys Therapeutics (MLYS) grant to its new CMO on August 10, 2026?

Mineralys Therapeutics granted Dr. Terry Ferguson a stock option for 135,000 shares and an RSU award for 102,400 shares. According to Mineralys, both awards are employment inducement grants under the 2025 Employment Inducement Incentive Award Plan, subject to multi-year vesting and continued service.

How do the stock options granted by Mineralys Therapeutics (MLYS) to Dr. Terry Ferguson vest?

The stock options for 135,000 shares vest over four years, starting August 10, 2026. According to Mineralys, 25% vests on the first anniversary, and the remaining 75% vests in equal monthly installments over the next three years, subject to continued service.

What is the vesting schedule for the 102,400 RSUs granted by Mineralys Therapeutics (MLYS)?

The 102,400 RSUs vest in four equal annual installments beginning August 10, 2026. According to Mineralys, 25% of the RSUs vest on each of the first four anniversaries of the vesting commencement date, contingent on Dr. Ferguson’s continued service with the company.

Why did Mineralys Therapeutics (MLYS) use Nasdaq Listing Rule 5635(c)(4) for Dr. Ferguson’s inducement awards?

Mineralys used Nasdaq Listing Rule 5635(c)(4) to grant equity as a material inducement to Dr. Ferguson’s employment. According to Mineralys, this rule allows equity awards to new employees outside shareholder-approved plans when tied directly to entering employment.

What is the Mineralys Therapeutics (MLYS) 2025 Employment Inducement Incentive Award Plan?

The 2025 Employment Inducement Incentive Award Plan authorizes inducement equity grants to new Mineralys employees. According to Mineralys, Dr. Terry Ferguson’s option and RSU awards were issued under this plan as part of his hiring package, consistent with Nasdaq Listing Rule 5635(c)(4).

Who is the recipient of the August 10, 2026 inducement awards at Mineralys Therapeutics (MLYS)?

The inducement awards were granted to Dr. Terry Ferguson, the newly appointed Chief Medical Officer. According to Mineralys, a majority of the company’s independent directors approved the option and RSU grants as a material inducement for him to join the company.